CenterLab’s anti-diabetic drug candidate CS02 meets primary endpoint in phase 2 trial
Taiwanese pharma company Center Laboratories (CenterLab) said that its anti-diabetic drug candidate CS02 has met the primary endpoint of a phase 2 clinical trial. According to Center Laboratories, the orally administered small molecule drug candidate delivered significant reductions in glycated hemoglobin (HbA1c) in comparison to the placebo group. The phase 2 clinical trial is a […]